NCT02122822View on ClinicalTrials.gov

Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

May 31, 2017

Conditions
Glioma
Interventions
BIOLOGICAL

gp96

vaccination of autologous gp96 derived from tumor tissue + basal treatment

Trial Locations (1)

Unknown

Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

Cure&Sure Biotech Co., LTD

INDUSTRY

NCT02122822 - Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 | Biotech Hunter | Biotech Hunter